A citation-based method for searching scientific literature

Michael S Roberts, David C Turner, Alberto Broniscer, Clinton F Stewart. J Chromatogr B Analyt Technol Biomed Life Sci 2014
Times Cited: 16







List of co-cited articles
59 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Rolf W Sparidans, Seng Chuan Tang, Luan N Nguyen, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
16
43

Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry.
Feng Qiu, Yanan Gu, Tingting Wang, Yingying Gao, Xiao Li, Xiangyu Gao, Shan Cheng. Biomed Chromatogr 2016
16
31

Pharmacokinetics of crizotinib in NSCLC patients.
Gerhard Hamilton, Barbara Rath, Otto Burghuber. Expert Opin Drug Metab Toxicol 2015
30
25

Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
Johannes J M Rood, Mark T J van Bussel, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. J Chromatogr B Analyt Technol Biomed Life Sci 2016
31
25

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Jean Cui, Michelle Tran-Dubé, Hong Shen, Mitchell Nambu, Pei-Pei Kung, Mason Pairish, Lei Jia, Jerry Meng, Lee Funk, Iriny Botrous,[...]. J Med Chem 2011
528
25


Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
18

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Giorgio Scagliotti, Rolf A Stahel, Rafael Rosell, Nick Thatcher, Jean-Charles Soria. Eur J Cancer 2012
63
18

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
N A G Lankheet, E E Schaake, H Rosing, J A Burgers, J H M Schellens, J H Beijnen, A D R Huitema. Bioanalysis 2012
9
33

Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hideki Hayashi, Yutaro Kita, Hirotoshi Iihara, Koumei Yanase, Yasushi Ohno, Chiemi Hirose, Maya Yamada, Kenichiro Todoroki, Kiyoyuki Kitaichi, Shinya Minatoguchi,[...]. Biomed Chromatogr 2016
28
18

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
M Herbrink, N de Vries, H Rosing, A D R Huitema, B Nuijen, J H M Schellens, J H Beijnen. Biomed Chromatogr 2018
31
18

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
18



Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
187
12

Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma.
Jacek Musijowski, Monika Filist, Piotr J Rudzki. Acta Pol Pharm 2014
9
22

Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.
Cynthia M Nijenhuis, Hilde Rosing, Jan H M Schellens, Jos H Beijnen. Bioanalysis 2014
12
16



An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Yi Zhen, Audrey Thomas-Schoemann, Lilia Sakji, Pascaline Boudou-Rouquette, Nicolas Dupin, Laurent Mortier, Michel Vidal, Francois Goldwasser, Benoit Blanchet. J Chromatogr B Analyt Technol Biomed Life Sci 2013
27
12


A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
Christine Bobin-Dubigeon, Alexandra Heurgue-Berlot, Olivier Bouché, Marie-Bernadette Amiand, Chantal Le Guellec, Jean-Marie Bard. Ther Drug Monit 2011
12
16

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
149
12

A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Toshiki Yanagi, Kanehiko Hisamichi, Masaki Matsuura, Kazutoshi Akasaka, Masami Tsuchiya, Yasuteru Kondo, Tooru Shimosegawa,[...]. Tohoku J Exp Med 2014
15
13

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
Lie Li, Ming Zhao, Fariba Navid, Keith Pratz, B Doug Smith, Michelle A Rudek, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2010
44
12

Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Jose María Moreno, Aneta Wojnicz, Juan Luis Steegman, Maria F Cano-Abad, Ana Ruiz-Nuño. Biomed Chromatogr 2013
13
15

Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study.
Xiao-wei Xu, Xin-juan Su, Yu-niao Zhang, Xiao-kang Zheng, Peng-fei Lv, Jie Hu. J Chromatogr B Analyt Technol Biomed Life Sci 2015
9
22

Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.
Mei Zhang, Grant A Moore, Liam J Fernyhough, Murray L Barclay, Evan J Begg. Anal Bioanal Chem 2012
8
25




A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Lionel Faivre, Charline Gomo, Olivier Mir, Fabrice Taieb, Audrey Schoemann-Thomas, Stanislas Ropert, Michel Vidal, Daniel Dusser, Alain Dauphin, Francois Goldwasser,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2011
47
12


Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
67
12

Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.
Andrea Davies, Alison K Hayes, Katy Knight, Sarah J Watmough, Munir Pirmohamed, Richard E Clark. Leuk Res 2010
38
12


A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
Elisa Pirro, Silvia De Francia, Francesca De Martino, Carmen Fava, Stefano Ulisciani, Giovanna Rege Cambrin, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo. J Chromatogr Sci 2011
26
12

Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
M Birch, P E Morgan, S Handley, A Ho, R Ireland, R J Flanagan. Biomed Chromatogr 2013
24
12


Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry.
Ling-Zhi Wang, Michelle Yi-Xiu Lim, Tan-Min Chin, Win-Lwin Thuya, Pei-Ling Nye, Andrea Wong, Sui-Yung Chan, Boon-Cher Goh, Paul C Ho. J Chromatogr B Analyt Technol Biomed Life Sci 2011
21
12

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Theodore R Johnson, Weiwei Tan, Lance Goulet, Evan B Smith, Shinji Yamazaki, Gregory S Walker, Melissa T O'Gorman, Gabriella Bedarida, Helen Y Zou, James G Christensen,[...]. Xenobiotica 2015
37
12

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Huiping Xu, Melissa O'Gorman, Tanya Boutros, Nicoletta Brega, Constantino Kantaridis, Weiwei Tan, Akintunde Bello. J Clin Pharmacol 2015
25
12


Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.
Kathryn Brown, Craig Comisar, Han Witjes, John Maringwa, Rik de Greef, Karthick Vishwanathan, Mireille Cantarini, Eugène Cox. Br J Clin Pharmacol 2017
64
12

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
J C-H Yang, L V Sequist, C Zhou, M Schuler, S L Geater, T Mok, C-P Hu, N Yamamoto, J Feng, K O'Byrne,[...]. Ann Oncol 2016
126
12


Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.
J W Findlay, W C Smith, J W Lee, G D Nordblom, I Das, B S DeSilva, M N Khan, R R Bowsher. J Pharm Biomed Anal 2000
365
12


Principles of therapeutic drug monitoring.
Wei Zhao, Evelyne Jacqz-Aigrain. Handb Exp Pharmacol 2011
17
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.